Department of Pathology, Saint-Louis Hospital, AP-HP.
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI).
Am J Surg Pathol. 2018 Apr;42(4):423-441. doi: 10.1097/PAS.0000000000001025.
We developed and validated an architecture-based grading for clear cell renal cell carcinoma (ccRCC) in an observational retrospective cohort study including 506 tumors (principal cohort, n=254; validation cohort, n=252). Study endpoints were disease-free survival (DFS) and cancer-specific survival (CSS). Relationships with outcome were analyzed using Harrell concordance index, time-dependent receiver operating characteristic curve, area under curve, and Cox regression model. An architecture-based grading was devised on positive likelihood ratio (LR+) for DFS at 50 months as follows: grade 1 (LR+<0.8), cystic, compact, acinar, clear cell papillary RCC-like, and/or regressive patterns; grade 2 (1.2≤LR+<5), large nest, alveolar, papillary, chromophobe/oncocytic cell-like, eosinophilic hyaline globule, and/or intratumoral inflammatory reaction patterns; grade 3 (5≤LR+<10), rhabdoid, tumor giant cell, enlarged vascular space, and/or hereditary leiomyomatosis renal cell carcinoma (HLRCC)-like patterns; grade 4 (LR+≥10), sarcomatoid, infiltrative growth patterns, and lymphatic invasion. In the principal cohort, 3-tier (grades 1-2, 3, and 4) and 4-tier architectural scores outperformed World Health Organization/International Society of Urological Pathology, and World Health Organization/ International Society of Urological Pathology+necrosis gradings for DFS and CSS, and constituted an independent predictor for DFS (hazard ratio [HR]=5.91; P<6.7E-10) and CSS (HR=4.49; P=2.2E-03), retained in the localized (pT1-3N0M0) ccRCC subgroup (HR=6.10; P=1.3E-07 for DFS, and HR=20.09; P=9.4E-05 for CSS). On comparing with integrated staging systems, architectural grade with 1 morphologic datum remained an independent predictor of CSS, as did University of California Los Angeles Integrated Staging System and SSIGN, and was associated with the highest HR (HR=2.60; P=9.1E-04 in all patients; HR=4.38; P=2.0E-05 in the localized ccRCC subgroup). Architecture-based score for ccRCC outperforms all other morphologic grading systems and constitutes an independent predictor for DFS and CSS. As the predictive values of 3-tier and 4-tier architecture-based scores were similar throughout the study, we proposed to keep the simplified version as the final score, and to define 3 risk groups as follows: low risk (grades 1 to 2), intermediate risk (grade 3), and high risk (grade 4).
我们在一项包括 506 个肿瘤的观察性回顾性队列研究中开发并验证了一种基于结构的透明细胞肾细胞癌(ccRCC)分级方法,该研究包括 254 例(主要队列)和 252 例(验证队列)。研究终点为无病生存(DFS)和癌症特异性生存(CSS)。使用 Harrell 一致性指数、时间依赖性接受者操作特征曲线、曲线下面积和 Cox 回归模型分析与结果的关系。基于阳性似然比(LR+)为 50 个月时的 DFS,设计了一种基于结构的分级方法如下:1 级(LR+<0.8),囊性、致密、腺泡、透明细胞乳头状 RCC 样和/或退行性模式;2 级(1.2≤LR+<5),大巢、肺泡、乳头状、嗜铬/嗜酸透明细胞样、嗜酸性透明小体和/或肿瘤内炎症反应模式;3 级(5≤LR+<10),横纹肌样、巨细胞瘤样、血管空间增大和/或遗传性平滑肌瘤病肾细胞癌(HLRCC)样模式;4 级(LR+≥10),肉瘤样、浸润性生长模式和淋巴血管侵犯。在主要队列中,3 级(1-2 级、3 级和 4 级)和 4 级结构评分在预测 DFS 和 CSS 方面优于世界卫生组织/国际泌尿病理学会和世界卫生组织/国际泌尿病理学会+坏死分级,并且是 DFS(风险比[HR]=5.91;P<6.7E-10)和 CSS(HR=4.49;P=2.2E-03)的独立预测因子,并保留在局限性(pT1-3N0M0)ccRCC 亚组中(DFS 的 HR=6.10;P=1.3E-07,CSS 的 HR=20.09;P=9.4E-05)。与综合分期系统相比,具有 1 个形态学数据的结构分级仍然是 CSS 的独立预测因子,加利福尼亚大学洛杉矶分校综合分期系统和 SSIGN 也是如此,并且与最高 HR(所有患者中的 HR=2.60;P=9.1E-04;局限性 ccRCC 亚组中的 HR=4.38;P=2.0E-05)相关。ccRCC 的基于结构的评分优于所有其他形态学分级系统,是 DFS 和 CSS 的独立预测因子。由于 3 级和 4 级基于结构的评分在整个研究中的预测值相似,因此我们建议保留简化版本作为最终评分,并将 3 个风险组定义为:低风险(1-2 级)、中风险(3 级)和高风险(4 级)。